Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

1.

Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies.

Grallert H, Dupuis J, Bis JC, Dehghan A, Barbalic M, Baumert J, Lu C, Smith NL, Uitterlinden AG, Roberts R, Khuseyinova N, Schnabel RB, Rice KM, Rivadeneira F, Hoogeveen RC, Fontes JD, Meisinger C, Keaney JF Jr, Lemaitre R, Aulchenko YS, Vasan RS, Ellis S, Hazen SL, van Duijn CM, Nelson JJ, März W, Schunkert H, McPherson RM, Stirnadel-Farrant HA, Psaty BM, Gieger C, Siscovick D, Hofman A, Illig T, Cushman M, Yamamoto JF, Rotter JI, Larson MG, Stewart AF, Boerwinkle E, Witteman JC, Tracy RP, Koenig W, Benjamin EJ, Ballantyne CM.

Eur Heart J. 2012 Jan;33(2):238-51. doi: 10.1093/eurheartj/ehr372. Epub 2011 Oct 14.

PMID:
22003152
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.

Sudhir K.

J Clin Endocrinol Metab. 2005 May;90(5):3100-5. Epub 2005 Feb 15. Review.

PMID:
15713711
[PubMed - indexed for MEDLINE]
3.

Lipoprotein-associated phospholipase A2 as a target of therapy.

Macphee CH, Nelson JJ, Zalewski A.

Curr Opin Lipidol. 2005 Aug;16(4):442-6. Review.

PMID:
15990594
[PubMed - indexed for MEDLINE]
4.

Lp-PLA2: an emerging biomarker of coronary heart disease.

Dada N, Kim NW, Wolfert RL.

Expert Rev Mol Diagn. 2002 Jan;2(1):17-22. Review.

PMID:
11963798
[PubMed - indexed for MEDLINE]
5.

Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.

Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F.

Mayo Clin Proc. 2007 Feb;82(2):159-65. Review.

PMID:
17290721
[PubMed - indexed for MEDLINE]
6.

The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma.

Tellis CC, Tselepis AD.

Biochim Biophys Acta. 2009 May;1791(5):327-38. doi: 10.1016/j.bbalip.2009.02.015. Review.

PMID:
19272461
[PubMed - indexed for MEDLINE]
Free Article
7.

[Lipoprotein associated phospholipase A2].

Rubinstein A, Izkhakov E.

Harefuah. 2011 Feb;150(2):136-40, 205. Review. Hebrew.

PMID:
22164942
[PubMed - indexed for MEDLINE]
8.

Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults.

Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, Warnick GR, McConnell JP.

Prev Cardiol. 2006 Summer;9(3):138-43. Review.

PMID:
16849876
[PubMed - indexed for MEDLINE]
9.
10.

Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction.

Sudhir K.

Vasc Health Risk Manag. 2006;2(2):153-6. Review.

PMID:
17319459
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.

Virani SS, Nambi V.

Curr Atheroscler Rep. 2007 Aug;9(2):97-103. Review.

PMID:
17877917
[PubMed - indexed for MEDLINE]
12.

Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target.

Packard CJ.

Curr Opin Cardiol. 2009 Jul;24(4):358-63. doi: 10.1097/HCO.0b013e32832bcb22. Review.

PMID:
19417639
[PubMed - indexed for MEDLINE]
13.

Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).

Tselepis AF, Rizzo M, Goudevenos IA.

Curr Pharm Des. 2011 Nov;17(33):3656-61. Review.

PMID:
22074435
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk